Crystax Oryzon Acquires Biopharmaceutical Crystax
Image obtained from Crystax Pharmaceuticals S.L. web site
The spin-off from the Universidad de Barcelona and the CSIC, Oryzon, specialized in new biomarkers and therapeutic targets in oncology and neurodegenerative diseases, acquired the biopharmaceutical Crystax Pharmaceuticals S.L., which focuses in developing new therapeutic molecules in cancer.
No comments yet.
Leave a comment
-
Recent Comments
nanobugle on The Nano School Box bushra on The Nano School Box Charles on Carbon Nanotube Membranes for … 
Magnetic Nanomedicin… on Nanomedicine Techniques to Visual… on Carbon Nanotube
